We thank our financial, public and institutional partners which have shown their confidence in us from the creation of the company and which are contributing to its future development.
InnoBio is a €139 M French venture capital fund, managed by CDC Enterprises. Its subscribers include the FSI (37%) and leading international pharmaceutical companies established in France such as Sanofi, GSK, Roche, Novartis, Pfizer, Lily, Ipsen, Takeda and Boehringer Ingelheim. The main objective of the fund is to make direct equity and quasi-equity investments in companies that provide innovative technology products and services in healthcare. Innobio’s investor team specializes in this sector and is led by Laurent Arthaud. InnoBio made its first investment in January 2010.
Contact: Philippe Boucheron – firstname.lastname@example.org
iXO Private Equity is a private equity firm investing in Venture Capital, LBO and Expansion Capital. Located in Toulouse, IXO is the most important French regional independent actor in private equity managing €240M. It invests from €2M to €10M per target company in the West and South of France.
Contact: Jean-Michel Petit – email@example.com